Literature DB >> 1079473

A rapid and specific radioimmunoassay for methotrexate.

V Raso, R Schreiber.   

Abstract

A sensitive and precise radioimmunoassay for methotrexate has been developed using antibody induced in rabbits, tritium-labeled methotrexate, and a nitrocellulose membrane separation technique. Antibody specificity was characterized by comparing the effectiveness of various related compounds to displace labeled methotrexate from the antibody-binding site. Assay of serum samples from persons receiving the drug was rapid and easy to perform. In a pharmacokinetic study of methotrexate, corresponding results were obtained when measurements were made by either enzymic assay or by radioimmunoassay. Drug concentrations could also be monitored in the cerebrospinal fluid and urine of patients on high-dose methotrexate therapy followed by citrovorum factor rescue. The system measured a little as 0.1 to 1 pmole of methotrexate, depending upon the antiserum used, and naturally occurring folates did not interfere with these determinations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079473

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].

Authors:  G E Janka; H Wiesner; F Bidlingmaier; R J Haas
Journal:  Klin Wochenschr       Date:  1979-04-17

Review 2.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

3.  A microbiological assay for the measurement of methotrexate in biological fluids.

Authors:  G C Icke; R E Davis; J Thom
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

Review 4.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 5.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

6.  Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea.

Authors:  H W Van Den Berg; R F Murphy; D G Kennedy
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Determination of methotrexate in biological fluids and a parenteral injection using terbium-sensitized method.

Authors:  Abolghasem Jouyban; Masoomeh Shaghaghi; Jamshid L Manzoori; Jafar Soleymani; Jalil Jalilvaez-Gharamaleki
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

8.  Optimized high performance liquid chromatography-ultraviolet detection method using core-shell particles for the therapeutic monitoring of methotrexate.

Authors:  Milagros Montemurro; María M De Zan; Juan C Robles
Journal:  J Pharm Anal       Date:  2015-12-17

9.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.